中国银河给予艾力斯推荐评级:核心产品快速放量,海外临床顺利推进
Group 1 - China Galaxy issued a report on August 29, recommending Elysium (688578.SH, latest price: 114 yuan) based on strong revenue and profit growth, driven by the rapid market penetration of Vomeprazole [1] - The commercialization of Golai Reza has commenced, and the local production of Platinib is accelerating [1] - Increased R&D investment and smooth progress in overseas clinical trials are highlighted as positive factors for the company [1] Group 2 - Nvidia's stock price has experienced a significant drop, resulting in a market value loss of 1.28 trillion yuan [1] - Investors expressed concerns over a $200 million earnings gap, leading to panic in the market [1]